CRISPR Therapeutics AG (CRSP) Q3 2025 10-Q Quarterly Report
Filed: Nov 10, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR CRISPR Therapeutics AG (CRSP) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 10, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
CRISPR Therapeutics AG Q3 2025 10-Q Analysis
Risk Factors
- • New regulatory risk: ongoing U.S. government shutdown since Oct 1, 2025 causing FDA, SEC furloughs and layoffs impacting product review timelines
- • Updated regulatory risk: potential prolonged delays in FDA's IND submissions and drug approvals due to staffing cuts and disrupted operations
- • Impactful compliance risk: federal funding uncertainty for FDA and SEC amid political events risks delayed regulatory approvals affecting commercialization
- • Operational risk: interruptions in government agency functions delay regulatory submissions and product development timelines essential for U.S. market entry
- • Financial risk: no material changes disclosed, carried-forward risks remain without updates on liquidity, debt maturity, or currency exposure
CRISPR Therapeutics AG Q3 2025 Quarterly FinancialsXBRL
Revenue
$889,000
▲ +47.7% YoY▼ -0.3% QoQ
Net Income
-$106M
▼ -23.9% YoY▲ +49.0% QoQ
Operating Margin
-14854.8%
▲ +343924bp YoY▲ +1085419bp QoQ
Net Margin
-11973.1%
▲ +230296bp YoY▲ +1140682bp QoQ
ROE
-5.6%
Total Assets
$2.2B
EPS (Diluted)
$-1.14
▼ -14.0% YoY▲ +52.5% QoQ
Operating Cash Flow
-$85M
▲ +20.8% YoY▲ +25.7% QoQ
Source: XBRL data from CRISPR Therapeutics AG Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on CRISPR Therapeutics AG
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.